Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALE long-term extension study of pegcetacoplan in C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis
2023-504625-39-00Phase 3Authorised
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Apellis Pharmaceuticals. Primary endpoint: Log-transformed urine protein-to-creatinine ratio over time. Planned start Aug 2023; status: authorised.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2023-504625-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504625-39-00.